冠昊生物
(300238)
| 流通市值：37.01亿 | | | 总市值：37.02亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 106,645,462.87 | 109,740,423.08 | 96,726,668.46 | 105,136,100.6 |
| 应收票据及应收账款 | 63,709,363.04 | 60,853,799.21 | 74,827,102.21 | 61,142,630.83 |
| 应收账款 | 63,709,363.04 | 60,853,799.21 | 74,827,102.21 | 61,142,630.83 |
| 预付款项 | 7,257,944.54 | 4,842,970.48 | 10,086,994.43 | 7,215,658.54 |
| 其他应收款合计 | 6,250,244.7 | 6,310,162.3 | 14,111,003.79 | 13,363,635.03 |
| 存货 | 75,276,629.78 | 70,836,315.79 | 68,970,276.51 | 71,601,478.41 |
| 其他流动资产 | 14,474,663.91 | 12,648,646.28 | 10,119,452.76 | 8,818,365.31 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 273,614,308.84 | 265,232,317.14 | 274,841,498.16 | 267,277,868.72 |
| 非流动资产: | | | | |
| 长期股权投资 | 19,316,439.23 | 16,825,242.45 | 16,796,101.2 | 16,925,116.83 |
| 其他权益工具投资 | 15,154,545.45 | 15,154,545.45 | 15,154,545.45 | 15,154,545.45 |
| 投资性房地产 | 8,680,514.29 | 8,791,798.33 | 8,903,082.37 | 9,014,366.41 |
| 固定资产 | 154,925,372.7 | 157,389,008.14 | 159,545,621.43 | 161,957,544.86 |
| 在建工程 | 124,105,646.48 | 100,487,550.91 | 84,918,583 | 73,991,443.33 |
| 使用权资产 | 11,938,658.04 | 13,509,884.94 | 15,081,111.84 | 16,089,869.59 |
| 无形资产 | 76,257,925.21 | 73,881,757.8 | 76,271,075.67 | 78,660,393.54 |
| 开发支出 | 25,568,848.9 | 23,970,646.52 | 21,603,062 | 20,473,785.26 |
| 商誉 | 1,753,899.07 | - | - | - |
| 长期待摊费用 | 3,510,134.61 | 3,760,160.5 | 4,015,746.82 | 3,693,020.38 |
| 递延所得税资产 | 15,055,246.69 | 15,138,799.36 | 14,878,028.49 | 14,966,060.55 |
| 其他非流动资产 | 438,500.02 | 605,384.49 | 359,500 | 390,884.48 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 456,705,730.69 | 429,514,778.89 | 417,526,458.27 | 411,317,030.68 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 730,320,039.53 | 694,747,096.03 | 692,367,956.43 | 678,594,899.4 |
| 流动负债: | | | | |
| 短期借款 | 21,014,583.21 | 22,516,249.88 | 23,518,669.32 | 24,519,463.77 |
| 应付票据及应付账款 | 8,554,075.76 | 8,633,079.21 | 8,004,001.15 | 29,323,170.62 |
| 应付账款 | 8,554,075.76 | 8,633,079.21 | 8,004,001.15 | 29,323,170.62 |
| 预收款项 | 978,836.12 | - | - | - |
| 合同负债 | 32,441,686.76 | 27,791,312.57 | 31,796,390.65 | 21,972,595.4 |
| 应付职工薪酬 | 15,763,873.9 | 12,828,327.53 | 8,748,804.4 | 17,836,628.5 |
| 应交税费 | 11,167,086.15 | 12,261,371.56 | 12,308,020.42 | 8,124,112.79 |
| 其他应付款合计 | 65,788,641.2 | 56,593,942.75 | 56,325,059.76 | 63,555,990.45 |
| 一年内到期的非流动负债 | 6,599,689.85 | 6,098,545.08 | 7,428,721.08 | 6,073,196.53 |
| 其他流动负债 | 1,979,279.4 | 1,735,628.36 | 1,300,111.12 | 1,311,058.67 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 164,287,752.35 | 148,458,456.94 | 149,429,777.9 | 172,716,216.73 |
| 非流动负债: | | | | |
| 长期借款 | 63,070,097.23 | 46,052,388.9 | 36,045,100.01 | 12,015,033.34 |
| 租赁负债 | 7,288,832.27 | 9,426,313.49 | 10,010,589.24 | 12,059,620.68 |
| 递延收益 | 19,733,382.03 | 20,037,859.56 | 20,342,337.09 | 20,646,814.62 |
| 递延所得税负债 | 4,866,165.84 | 4,875,207.09 | 4,886,052.53 | 4,896,968.28 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 94,958,477.37 | 80,391,769.04 | 71,284,078.87 | 49,618,436.92 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 259,246,229.72 | 228,850,225.98 | 220,713,856.77 | 222,334,653.65 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 265,155,701 | 265,155,701 | 265,155,701 | 265,155,701 |
| 资本公积 | 600,545,861.28 | 600,545,861.28 | 600,268,565.98 | 600,268,565.98 |
| 其他综合收益 | -46,575,005.98 | -46,504,259.75 | -46,543,836.87 | -46,462,910.94 |
| 盈余公积 | 47,110,231.52 | 47,110,231.52 | 47,110,231.52 | 47,110,231.52 |
| 未分配利润 | -319,827,806.21 | -327,515,700.41 | -331,086,233.7 | -345,477,748.45 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 546,408,981.61 | 538,791,833.64 | 534,904,427.93 | 520,593,839.11 |
| 少数股东权益 | -75,335,171.8 | -72,894,963.59 | -63,250,328.27 | -64,333,593.36 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 471,073,809.81 | 465,896,870.05 | 471,654,099.66 | 456,260,245.75 |
| 负债和股东权益合计 | 730,320,039.53 | 694,747,096.03 | 692,367,956.43 | 678,594,899.4 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-03-06 |
| 审计意见(境内) | | | | 标准无保留意见 |